A 6-year-old boy is brought to the clinic by his mother for a routine health check. His father was recently diagnosed with smear-positive pulmonary TB and is starting treatment. The child is asymptomatic, with normal growth and development. Physical examination is unremarkable. Mantoux test (5 TU) shows 12 mm induration at 48 hours. Chest X-ray is completely normal. What is the most appropriate next step in management?

Explanation

## Management of TB-Exposed Child: Latent TB Infection (LTBI) ### Clinical Scenario: TB Contact with LTBI **Key Point:** This asymptomatic child with a positive Mantoux test and normal chest X-ray has **latent TB infection (LTBI)**, not active TB disease. The critical distinction determines treatment strategy. ### Diagnostic Classification | Feature | This Child | Active TB | LTBI | | --- | --- | --- | --- | | **Symptoms** | None | Cough, fever, FTT | Asymptomatic | | **Chest X-ray** | Normal | Infiltrates/lymphadenopathy | Normal | | **Mantoux test** | 12 mm (positive) | Positive | Positive | | **Infectiousness** | No | Yes (if smear+) | No | | **Risk of progression** | ~5% lifetime | Already active | 5–10% in children | ### Why IPT (Isoniazid Preventive Therapy) is Indicated **High-Yield:** WHO and Indian TB guidelines recommend IPT for: 1. **TB contacts** (household or close) with positive TST/Mantoux and normal CXR 2. **Children <5 years** exposed to smear-positive TB (regardless of TST status) 3. **HIV-positive** individuals with positive TST 4. **Immunocompromised** children (malnutrition, immunosuppressive therapy) This child meets criteria #1 (father is smear-positive) and is age 6 (near the cutoff for contact prophylaxis). ### IPT Regimen **Mnemonic: "IPT = I-N-H alone for 6 months"** - **Drug:** Isoniazid monotherapy (5–10 mg/kg/day, max 300 mg/day) - **Duration:** 6 months (some guidelines: 3 months if <5 years) - **Monitoring:** Monthly clinical review, baseline and periodic LFTs - **Efficacy:** ~90% reduction in progression to active TB ### Why Other Options Are Incorrect **Option A (Full anti-TB therapy):** Reserved for **active TB disease**, not LTBI. This child has no symptoms, no radiological findings, and no evidence of tissue invasion. Over-treatment increases drug toxicity risk and promotes resistance. **Option C (Repeat Mantoux):** Not indicated. A single positive Mantoux in a TB contact is sufficient for diagnosis of LTBI. Repeating does not change management. **Option D (Observe without treatment):** Dangerous. TB contacts have a 5–10% lifetime risk of progression to active disease. IPT reduces this by ~90%. Withholding treatment in a child with recent exposure is substandard care. ### Clinical Pearl: Age Considerations **Clinical Pearl:** Children <5 years with TB contact should receive IPT **regardless of Mantoux status** (because TST may be falsely negative early in infection). This child is 6 years old and Mantoux-positive, so IPT is clearly indicated. ### Contraindications to IPT - Active TB disease (treat with full regimen instead) - Isoniazid resistance (use alternative: rifampicin or levofloxacin) - Baseline hepatic impairment (LFTs >3× upper limit of normal) - Prior isoniazid-induced hepatitis ### Monitoring During IPT 1. **Clinical:** Monthly assessment for symptoms of active TB 2. **Biochemical:** Baseline LFTs; repeat if symptoms develop 3. **Adherence:** Ensure completion of full 6-month course 4. **Post-IPT:** No further monitoring unless TB symptoms develop [cite:Park 26e Ch 7 (TB Prevention in Children)] [cite:WHO Guidelines on TB Preventive Therapy 2020] [cite:NTEP India (National TB Elimination Programme)]